The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
As2O3: an inorganic arsenic compound; a by-product of metal smelting operations. This small-molecule arsenic compound shows antineoplastic activity. The
mechanism of action of arsenic trioxide is not completely understood.
This agent causes damage to or degradation of the promyelocytic
leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion
protein; induces apoptosis in acute promyelocytic leukemia (APL) cells
and in many other tumor cell types; promotes cell differentiation and
suppresses cell proliferation in many different tumor cell types; and
The term "arsenic trioxide" was found in the following pages: